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Guillain–Barré syndrome (GBS) is an acute peripheral neuropathy that develops as a 
result of post-infectious immune-mediated nerve injury. It can be classified into classic 
and variant GBS. Acute motor axonal neuropathy (AMAN) is a subtype of GBS with the 
key clinical features of pure motor weakness, areflexia, absence of sensory symptoms, 
and lack of neurophysiologic evidence of demyelination. We reported a case of acute 
motor axonal neuropathy in association with hepatitis E infection. A young woman was 
referred to us after a period of nausea, fever, and diarrhea. She had unexplained muscle 
weakness at admission and has been diagnosed with acute hepatitis E infection. A rig-
orous clinical neurological assessment revealed bilateral symmetrical weakness, which 
affects the lower limbs more than the upper limbs, with no evidence of sensory involve-
ment. Neurophysiological measurements indicated acute axonal injury without clues to 
demyelination. A diagnosis of acute motor axonal neuropathy subtype has been made, 
to which she only received supportive therapy. The symptoms resolved spontaneously 
and full recovery of motor function was attained after 35 days of weakness onset with 
complete normalization of neurophysiologic parameters.
Keywords: Guillain–Barré syndrome, acute motor axonal neuropathy, hepatitis e, muscle weakness, nerve 
conduction study
INtRoDUCtIoN
Guillain–Barré syndrome (GBS) is an acute peripheral neuropathic disease characterized by 
ascending flaccid paralysis of symmetrical distribution that can present with motor and/or sen-
sory symptoms (1). GBS comprises the most common form of acute inflammatory demyelinating 
neuropathy (AIDP) as well as other variants like Miller Fisher syndrome, acute motor and sensory 
axonal neuropathy, and acute motor axonal neuropathy (2).
Guillain–Barré syndrome is caused by post-infectious immunological modulation that leads to 
immunologically mediated damage of peripheral nerve parts (myelin, axon, or both) which may 
present with mixed sensorimotor or pure motor symptoms. Hepatitis viruses are among the emerg-
ing pathogens that could be encountered in the context of GBS (1). Specifically, hepatitis E infection 
was described in association with classical GBS or its variants, although none of the latter has been 
confirmed to lie in the pure motor category of GBS (3–7).
In our case report, we describe a woman with acute pure motor subtype of GBS that has devel-
oped in association with hepatitis E infection and recovered spontaneously in parallel with liver 
functions normalization.
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Case RepoRt
A 19-year-old Iraqi woman sought care for bilateral lower limb 
weakness without sensory symptoms during her 28th week of 
pregnancy. The patient suffered 3  days of fever associated with 
nausea, decreased appetite, and diarrhea. One day after fever ces-
sation, she developed bilateral lower limb weakness. She has been 
admitted to our hospital 24 h after the onset of lower limb weakness 
for further evaluation. Her initial blood work-up revealed hypoka-
lemia for which she was thought to have developed weakness and 
received intravenous potassium-containing fluids. Weakness 
failed to improve despite normalization of serum potassium level. 
3 days after the onset of weakness, she has been referred to us for 
further neurological assessment. At this point, she noticed that her 
lower limbs weakness has increased. Additionally, her upper limbs 
started to develop mild weakness. The patient reported uneventful 
pregnancy and no history of drugs intake. She had no travel his-
tory or contact with people suffering from similar symptoms. She 
reported eating from street food vendors.
Neurological examination revealed a modified MRC muscle 
power grade of 2/5 for dorsiflexors, plantar flexors, and knee 
flexors and extensors, 3/5 for hip flexors and abductors, and −4/5 
for finger intrinsic muscles, wrist flexors and extensors, elbow 
flexors and extensors, and shoulder abductors. Her lower limb 
deep tendon reflexes were bilaterally absent. No evidence of 
cranial nerves or cerebellar involvement has been noted. In addi-
tion, her sensory examination was completely normal. Her vital 
signs were normal. General physical examination was evident 
for conjunctival icterus. Tender hepatomegaly was noted during 
abdominal examination. Her cardiac and respiratory functions 
were normal.
Laboratory investigation showed normal complete blood 
count and ESR. Her serum electrolytes, blood urea, and serum 
creatinine were normal. Liver function tests showed elevated 
total serum bilirubin level (2.8 mg/dL, reference 0.2−1.2 mg/dL), 
serum alanine transaminase (ALT  =  829  U/L, reference 
5−34 U/L), and aspartate transaminase (AST = 471 U/L, reference 
0−55  U/L). Serum ceruloplasmin level was normal. Deranged 
coagulation profile is also evident [Prothrombin time (PT) = 16 s, 
normal range: up to 13 s; activated Partial Thromboplastin time 
(aPTT) = 41, normal range: up to 36 s] along with reduced serum 
albumin level (2.2 g/dL, normal range: 3.5−5.2 g/dL). Hepatitis 
E antibodies assessment using enzyme-linked immunosorbent 
assay method revealed elevated level of IgM (25.7 IU/ml, normal 
<2 IU/ml) as well as IgG level (15.9 IU/ml, normal <2 IU/ml). 
General stool examination revealed liquid feces with no evidence 
of blood or pus. Serological testing was negative for hepatitis 
A, B, and C, cytomegalovirus, Epstein–Barr virus, and human 
immunodeficiency virus. Serum antinuclear antibody (ANA) 
and thyroid function test were normal. We have been hindered 
from doing a lumbar puncture and cerebrospinal fluid analysis 
because of the bleeding tendency revealed by prolonged PT and 
PTT. Additionally, the patient refused to undergo a lumbar punc-
ture procedure. Patient’s abdominal and pelvic ultrasonographic 
examination revealed hepatomegaly.
Initial nerve conduction study (NCS) (7 days after the onset 
of weakness), showed evidence of axonal motor neuropathy of 
symmetrical distribution affecting the lower limbs more than 
the upper limbs with normal sensory NCS parameters. Needle 
Electromyography (EMG) study decreased recruitment pattern, 
consistent with acute onset neurogenic process. Repetitive nerve 
stimulation targeted to detect deficit associated with periodic 
paralysis was normal.
These findings were consistent with a diagnosis of acute motor 
axonal neuropathy variant of GBS in association with hepatitis 
E infection (as indicated by the clinical scenario, deranged liver 
function test, and serological evidence of hepatitis E antibody). 
The patient has been given no specific treatment except for close 
observation and supportive measures. Repeated NCS/EMG after 
35 days of weakness onset (see Table 1) showed full recovery of 
motor neurophysiological parameters. These changes have been 
paralleled by clinical improvement in weakness and normaliza-
tion of liver function test values.
DIsCUssIoN
Hepatitis E infection is considered among the most common 
feco-orally transmitted hepatitis in developing countries (8). 
Many case reports have documented the association of hepatitis 
E infection with a variety of neurological manifestations includ-
ing encephalitis and different types of neuropathies (9, 10). Of 
importance are those with reported peripheral neuropathic 
diseases like neuralgic amyotrophy, ataxic neuropathy, and AIDP 
or GBS (11, 12). Furthermore, some of GBS variants, like Miller 
Fisher syndrome and acute motor and sensory Axonal variant, 
have been reported by others (5, 12).
Pure motor or mixed sensorimotor fibers involvement catego-
rizes GBS into different subtypes, with the underlying pathologic 
mechanisms being either demyelination or axonopathy (1). 
AMAN is a subtype of GBS characterized by pure motor involve-
ment and absence of evidence of demyelination in electrophysi-
ological tests (2).
Acute motor axonal neuropathy was linked to Campylobacter 
jejuni and Zika virus infection in the literatures (13, 14). There is 
uncertainty about the frequency with which AMAN was reported 
and this was claimed to be as a consequence of variability in 
infectious agent exposure according to the geographical areas. 
Nevertheless, AMAN has an estimated incidence of 30–65% in 
Asia and Central and South America (1).
To our best knowledge, this is the first case report of AMAN 
that has developed in association with acute hepatitis E infection 
in an immunocompetent pregnant woman and has recovered 
rapidly and spontaneously. Van den Berg et al. have mentioned 
a single case out of 201 GBS cases in the Netherlands, in which 
neurophysiologic evidence of AMAN has been documented 
in the presence of IgM anti-HEV antibody (15). However, the 
recovery pattern was prolonged and the treatment status is 
unknown. In our case, the diagnosis of hepatitis E infection was 
based on finding of high hepatitis E IgM in addition to rising 
level of IgG to greater than fivefolds. We did not determine viral 
RNA load using polymerase chain reaction-reverse transcriptase 
technique. Nevertheless, hepatitis E antibodies profile sufficed for 
the diagnosis of acute hepatitis E infection (16). Needless to say, 
serum transaminases profile (ALT is higher elevated than AST) 
taBle 1 | Comparison of motor nerve conduction study (NCS) results at onset and resolution of motor weakness.
parameters R. sural l. sural R. peroneal l. peroneal R. tibial l. tibial R. median l. median R. ulnar l. ulnar
Initial NCs (7 days after onset of weakness)
dCMAP amp. (mV) 0.5 0.7 2.1 1.9 3.8 4.0 3.2 3.4
Normal values (mV) >2.0 >4.0 >4.4 >6.0
DML (ms) 4.2 4.1 3.0 3.1 2.4 2.5 2.46 2.75
Normal values (ms) <6.5 <5.8 <4.2 <3.1
MCV (m/s) 51.7 50.7 49.1 50.1 58.8 57.0 54.7 54.0
Normal values (m/s) >40 >40 >50 >50
SNAP amp. (μV) 14 15 23 22 21 24
Normal values (μV) >10 >20 >18
SCV (m/s) 55.2 54.3 63.3 61.2 60.3 60.9
Normal values (m/s) >36 >45 >44
Resolution of motor weakness (35 days after weakness onset)
dCMAP amp. (mV) 4.3 4.1 4.3 4.7 5.0 5.3 4.9 5.1
DML (ms) 3.7 3.9 2.6 3.0 2.3 2.4 2.6 2.9
CV (m/s) 57.7 58.8 50.2 51.0 58.9 56.9 52.2 52.1
SNAP amp. (μV) 16 13 24 21 23 -
SCV (m/s) 53.5 52.1 62.5 60.8 59.4 -
R, right; L, left; dCMAP, distal compound muscle action potential amplitude; MCV, motor conduction velocity; SCV, sensory conduction velocity; SNAP, sensory nerve action 
potential.
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does agree with a predominant hepatocellular injury, among 
which, hepatotropic infection is a common type (17, 18). Arguing 
against the diagnosis of viral hepatitis is also a possibility; how-
ever, the lack of evidence of alternative diagnosis of hepatitis like 
drug induced, alcoholic, or immune hepatitis could be excluded 
by lack of history of drug or alcohol intake and laboratory clues of 
immune hepatitis. Based on the clinical and neurophysiological 
features, the patient developed an acute motor peripheral neu-
ropathy of ascending pattern with no clues to sensory involve-
ment. Absence of alternative diagnosis was confirmed by absence 
of indicators of vasculitic neuropathy (normal ESR and ANA) or 
possible myasthenia gravis or periodic paralysis (normal repeti-
tive nerve stimulation study). We collected enough evidence to 
reach level 2 diagnostic certainties according to Brighton’s criteria 
for diagnosing GBS (19).
Although previous case reports showed presence of anti-
GM1 and anti-GM2 anti-ganglioside antibodies in cases of GBS 
preceded by hepatitis E infection (20–22), we could not catch 
the opportunity to report anti-ganglioside antibodies in our 
case due to their unavailability as routine tests. Furthermore, 
anti-ganglioside antibodies are not required for the diagnosis of 
AMAN according to Brighton’s criteria (19).
Hiraga et al. described a rapid recovery pattern in 27% of 44 
cases of AMAN (23). All these cases required treatment with 
either immunoglobulin or plasmapheresis and none showed a 
spontaneous recovery pattern. Our case scenario fits into the rapid 
pattern of recovery. Additionally, the recovery was complete and 
spontaneous with no need for any specific therapeutic interven-
tion. Rapid and spontaneous recovery has been formerly reported 
in a case of AIDP associated with hepatitis E infection (6). This 
would suggest that the presence of hepatitis E is an indicator of 
favorable recovery pattern in the context of AMAN.
The mechanism by which hepatitis E virus can cause neuro-
logical injury is not completely understood. It has been suggested 
that viral molecular mimicry to a neural antigen could serve to 
enhance immunological reaction (1, 2). In our case, it seems 
that rapid recovery could be the result of clearance of the viral 
molecular particle, which presumably mimics axonal protein, by 
the immune system.
CoNClUDING ReMaRKs
The number of causative pathogens associated with GBS and 
its variants are expanding. We reported a case of AMAN vari-
ant of GBS in association with acute hepatitis E virus infection. 
This case highlights the importance of diagnosing AMAN in 
the context of hepatitis E and encourages further research to 
underpin the mechanism of axonal injury in AMAN variant. It 
also underscores the favorable, spontaneous recovery of AMAN 
in association with acute hepatitis E infection.
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